Ernexa Therapeutics develops cell therapies for advanced cancer and autoimmune disease using engineered induced pluripotent stem cells that are transformed into synthetic allogeneic induced mesenchymal stem cells. News about the company centers on ERNA-101, its lead iMSC candidate for ovarian cancer, including preclinical tumor-model results, immuno-oncology combinations and scientific discussions of the ovarian cancer treatment landscape.
Company updates also cover ERNA-201 for autoimmune inflammation, regulatory interactions tied to cell-therapy development, investor presentations, collaboration or market-entry programs, and capital-structure actions such as common-stock reverse splits and Nasdaq listing compliance.
Ernexa Therapeutics (ERNA) will present new ERNA-101 preclinical ovarian cancer data in a Flash Talk at MD Anderson Cancer Center. The presentation is scheduled for October 6, 2026, at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and MD Anderson in Houston.
In animal models of high-grade serous ovarian cancer, ERNA-101 promoted immune cell recruitment and was associated with tumor regression and enhanced survival. Combined with PD-1 checkpoint blockade, a treatment that helps immune cells attack cancer, it achieved complete tumor control and durable responses in the majority of treated animals. The combination findings were reproduced in a larger cohort.
Ernexa Therapeutics (Nasdaq: ERNA) highlighted Robert J. Spiegel’s board appointment as it advances ERNA-101 toward clinical development for platinum-resistant ovarian cancer.
The company has completed IND-enabling preclinical studies, studies supporting an application to begin human testing, and clinical-grade manufacturing is underway. Ernexa targets an investigational new drug (IND) submission in fourth-quarter 2026, followed by a first-in-human study in first-quarter 2027. In an ovarian cancer model, ERNA-101 combined with anti-PD-1 demonstrated complete tumor clearance and 100% survival; these were preclinical findings, not human results.
The CEO Corner discussion linked Spiegel’s oncology and regulatory experience to the upcoming development milestones. Ernexa is also advancing ERNA-102 and ERNA-103 and sees potential to expand ERNA-101 into additional difficult-to-treat solid tumors.
Ernexa Therapeutics (ERNA) reported animal safety results for ERNA-101 across three studies supporting its planned transition toward human testing. A 50-day repeat-dose toxicology study found no treatment-related adverse findings at any tested dose; a single-dose assessment found no acute cytokine release. No teratomas, or unwanted tumors, were observed through the six-month tumorigenicity study’s animal-observation phase, but microscopic tissue evaluation remains ongoing. A five-week distribution study detected no significant ERNA-101 signal in tumor-free animals or non-tumor tissues.
Manufacturing is underway. Ernexa plans an investigational new drug application in Q4 2026 for platinum-resistant ovarian cancer, with human testing subject to clearance and initial clinical data expected in Q4 2027.
Ernexa Therapeutics (ERNA) was selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa.
Chief Executive Officer Sanjeev Luther will present on October 6, 2026, focusing on ERNA-101 and its planned initial clinical path in platinum-resistant ovarian cancer. Ernexa remains on track for a planned investigational new drug application submission in 2026. Previously announced animal studies found complete tumor clearance and long-term survival in two-thirds of animals treated with ERNA-101 plus anti-PD-1 therapy in an independent study. An earlier ovarian cancer study reported complete tumor clearance and 100% survival through follow-up with the combination.
Ernexa Therapeutics (ERNA) has appointed Robert J. Spiegel, M.D., FACP, an experienced biopharmaceutical executive and oncologist, to its Board of Directors as the company advances its lead cell therapy candidate ERNA-101 toward clinical development.
Dr. Spiegel previously served as Chief Medical Officer at Schering-Plough Research Institute from 1998 to 2009 and at PTC Therapeutics from 2014 to 2016. He contributed to the development and approval of multiple therapies, including temozolomide and alpha-interferon, and participated in more than 30 successful New Drug Applications. He currently leads Spiegel Consulting, serves as Associate Professor of Medicine at Weill Cornell Medical College, and sits on several biotechnology and pharmaceutical company boards. Ernexa is progressing ERNA-101, an allogeneic iPSC-derived iMSC cell therapy initially focused on ovarian cancer, toward first clinical evaluation.
Ernexa Therapeutics (ERNA) reported positive preliminary preclinical data for ERNA-201 in a collagen-induced arthritis model and outlined a refocused oncology strategy centered on ERNA-101 and its synthetic iMSC platform.
In mice, several ERNA-201 lead candidates reduced disease severity and improved clinical arthritis scores versus untreated controls, consistent with the program’s anti-inflammatory design and providing preclinical proof-of-concept in inflammatory and autoimmune disease. Because ERNA-201 uses the same synthetic iMSC architecture as Ernexa’s oncology programs, these findings support the versatility of the allogeneic, off-the-shelf platform.
Ernexa is pausing additional ERNA-201 preclinical spend to concentrate capital and operations on ERNA-101, aiming for an IND submission for platinum-resistant ovarian cancer in Q4 2026 and initial clinical data in Q4 2027, while expanding its oncology pipeline and exploring collaborations.
Ernexa Therapeutics (ERNA)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on Wednesday, September 16, 2026, at 12:00 p.m. ET.President and CEO Sanjeev Luther will give an overview of Ernexa’s focused oncology strategy, recent progress with its lead cell therapy candidate ERNA-101, and the company’s off-the-shelf induced mesenchymal stem cell (iMSC) platform. The session will take place in the Kennedy I room on the 4th floor. Management will also be available for one-on-one meetings with qualified investors during the conference.
Ernexa Therapeutics (Nasdaq: ERNA) announced its participation in the Virtual Investor “Why Now” on-demand conference, where President and CEO Sanjeev Luther presented the company’s investment thesis and strategic outlook.
The webcast covers Ernexa’s planned transition to a clinical-stage company, with lead candidate ERNA-101 advancing toward a planned IND filing and first-in-human Phase 1 trial, based on its differentiated off-the-shelf iMSC platform and encouraging preclinical ovarian cancer data. The on-demand video is now available for viewing.
Ernexa Therapeutics (Nasdaq: ERNA) appointed veteran biotech executive and corporate attorney David Polinsky to its Board of Directors as the company prepares to enter the clinic with its lead cell therapy program ERNA-101.
According to Ernexa, the company plans to submit an Investigational New Drug (IND) application for ERNA-101 in the third quarter of 2026 and to initiate its first Phase 1 clinical study in the fourth quarter of 2026. Polinsky brings more than 25 years of experience in oncology, capital markets, M&A and corporate governance, and currently serves as Chief Financial Officer of Rafael Holdings (NYSE: RFL). His background includes leading finance, legal and strategy functions, helping establish Rafael Holdings as an independent NYSE-listed company after its 2018 spin-off, and helping lead a 2025 merger with Cyclo Therapeutics and an approximately $25 million rights offering. Ernexa’s leadership highlights this appointment as strengthening governance and strategic capabilities ahead of its transition to a clinical-stage company.
Ernexa Therapeutics (Nasdaq: ERNA) released a new CEO Corner video in which President and CEO Sanjeev Luther outlines the scientific rationale for ERNA-101, an allogeneic off-the-shelf induced mesenchymal stem cell (iMSC) therapy designed to modulate the immunosuppressive tumor microenvironment and support combination cancer treatments.
According to Ernexa, preclinical studies showed complete tumor elimination and 100% long-term survival in an ovarian cancer model when ERNA-101 was combined with PD-1 blockade, with independent validation reporting complete tumor clearance and durable survival in about two-thirds of treated animals. The company reports completion of manufacturing process development, initiation of engineering batch production, ongoing IND-enabling work, and maintains guidance for an IND submission in Q3 2026 and a planned Phase 1 trial in Q4 2026, initially targeting roughly 15,000 U.S. women annually with platinum-resistant ovarian cancer.